Sheldon Preskorn

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)

Maggie Fedgchin, Madhukar H. Trivedi, Ella Daly et al. · The International Journal of Neuropsychopharmacology · 2019 · 590 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

Sheldon Preskorn, Bryan Baker, Sheela Kolluri et al. · Journal of Clinical Psychopharmacology · 2008 · 511 citations

Medicine, Pharmacology, Pharmacotherapy +17

Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.

Sheldon Preskorn · PubMed · 1995 · 328 citations

Medicine, Pharmacotherapy, Psychiatry +17

Evidence of the Dual Mechanisms of Action of Venlafaxine

Anne T. Harvey, Richard L. Rudolph, Sheldon Preskorn · Archives of General Psychiatry · 2000 · 301 citations

Medicine, Pharmacology, Pharmacotherapy +16

Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression

Mark S. Kramer, Andrew Winokur, Jeffrey E. Kelsey et al. · Neuropsychopharmacology · 2003 · 259 citations

Medicine, Pharmacology, Pharmacotherapy +15